8431 results for "canc*"

in 52.01 milliseconds.

• Spatial Biology of Cancer of Unknown Primary

  Dac EGAC50000000720

• Studying ctDNA signal in plasam whole genome sequencing from high risk Breast Cancer patients

  We apply fragmentomics and minimal residue disease tools to find out signals from ctDNA in high risk Breat Cancer patients.

  Study EGAS50000001830

• Transcriptomics for IMMU-BC1 cohort

  The goal of IMMUcan is to understand how the immune system interacts with tumors and how therapeutic interventions influence this interaction. This cohort includes metastatic Triple Negative Breast Cancer (mTNBC) patients, naïve of treatment in the metastatic settings, treated in 1st line with chemotherapy or chemo-immunotherapy This dataset contains transcriptomics data processed with the STAR pipeline. Two sequencing kits were employed: Roche KAPA for high-quality RNA samples and Takara SMART-Seq Stranded for samples with limited RNA quantities. It contains gene-level counts.

  Dataset EGAD50000002269

• Variant calling for IMMU-BC1 cohort

  The goal of IMMUcan is to understand how the immune system interacts with tumors and how therapeutic interventions influence this interaction. This cohort includes metastatic Triple Negative Breast Cancer (mTNBC) patients, naïve of treatment in the metastatic settings, treated in 1st line with chemotherapy or chemo-immunotherapy This dataset contains whole exome sequencing data from tumor and matching germline samples processed with the Vegan pipeline. It includes SNP and CNV calling.

  Dataset EGAD50000002270

• Biopsy and resection samples of HCC and non-tumor tissue

  A total of 16 patients with primary liver cancer, who first underwent diagnostic biopsy and then surgical resection shortly afterwards (median 27 days) were included. Tumor and non-tumor biopsy and resection tissue were analyzed by RNA sequencing. Total RNA from frozen tumor- and non-tumor tissue from biopsy and resection specimens was extracted using the ZR-Duet DNA and RNA MiniPrep Plus kit (Zymo Research) according to the manufacturer’s instructions. Prior to extraction, frozen tissues were crushed in liquid nitrogen to facilitate lysis. Extracted RNA was quantified using the Qubit Fluorometer (Thermo Fisher Scientific). 200 ng total RNA was used for RNAseq library prep with the TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero Gold (Illumina) according to the manufacturer’s specifications. Paired-End sequencing was performed on a Novaseq 6000 (Illumina) with 51 cycles at the Genomics Facility Basel according to the manufacturer’s guidelines.

  Dataset EGAD50000002291

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  Whole genome sequencing of the matching blood from high risk breast cancer patients

  Dataset EGAD50000002653

• Study cfDNA molecular profiling for finding cancer signal in high risk Breast Cancer patients

  cfmedip methylation profiling CM from plasma cfDNA of high risk breast cancer patients

  Dataset EGAD50000002654

• FGFR2b Project Biliary Tract Cancer RNA Sequencing Data

  FASTQ files of RNA Sequencing data for the FGFR2b project.

  Dataset EGAD50000002899

• Germline WES of serrated polyposis syndrome

  The serrated polyposis syndrome (SPS) is a disease with a mainly unknown inherited genetic basis characterized by the presence of multiple and/or large serrated polyps in the colon and a higher associated risk for colorectal cancer (CRC). The objective of the present study was to identify new SPS/CRC germline predisposition genes by using whole-exome sequencing in two affected SPS patients from the same family.

  Study EGAS50000000765

• SOLTI- Arianna trial

  The main hypothesis of the study is that enzalutamide induces a significant proliferative arrest in HR+/HER2-negative breast cancer falling into the PAM50 HER2-E subtype. Patient population included males or pre/post-menopausal women with advanced HR+/HER2- ABC resistant to endocrine therapy, received ENZ 160 mg/day until disease progression. Patients were assigned to different cohorts according to PAM50 intrinsic subtypes identified in the pre-treatment tumor biopsy: Cohort A included pts with HER2-E and Cohort B pts with Luminal A/B tumors. Centralized molecular assessment was done at pre-treatment and C1D15.

  Study EGAS50000001979